Replimune Group Inc
NASDAQ:REPL
Replimune Group Inc
NASDAQ:REPL
Price:
5.92 USD
-8.07%
Market Closed
Updated:
May 20, 2024
Replimune Group Inc
Income from Continuing Operations
|
Replimune Group Inc
Income from Continuing Operations Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Replimune Group Inc
NASDAQ:REPL
|
Income from Continuing Operations
-$210m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$456m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Replimune Group Inc's Income from Continuing Operations?
Income from Continuing Operations
-210m
USD
-210m
USD
Based on the financial report for Dec 31, 2023, Replimune Group Inc's Income from Continuing Operations amounts to -210m USD.
What is Replimune Group Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-47%
-47%
Over the last year, the Income from Continuing Operations growth was -34%. The average annual Income from Continuing Operations growth rates for Replimune Group Inc have been -41% over the past three years , -47% over the past five years .
You don't have any saved screeners yet
